(RTTNews) - Replimune Group, Inc. (REPL), Tuesday announced that the U.S. Food and Drug Administration has accepted the Biologics License Application for RP1 in combination with Nivolumab for the ...

Patients were randomly assigned to receive either subcutaneous nivolumab, administered as a flat dose of 1200 mg co-formulated with 20,000 units of hyaluronidase every 4 weeks, or IV nivolumab at ...

The phase 3 CheckMate 649 trial showed that nivolumab plus chemotherapy significantly improved long-term overall survival in ...

Five-year data shows lasting benefit for patients with advanced gastroesophageal cancers treated with nivolumab and chemotherapy.

NP-101 plus nivolumab and ipilimumab demonstrated activity in patients with metastatic EP-NECs that were refractory to chemotherapy.

The biologics license application for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma was accepted by the ...

are thought to induce MG. Nivolumab is a monoclonal antibody that enhances the immune response against tumours by blocking inhibitory signals of cytotoxic T-lymphocytes antigen-4 and programmed cell ...

The investigational advanced melanoma combination therapy consisting of RP1 and nivolumab have a PDUFA action date of July 22 ...

The study enrolled 680 patients who were randomized after surgery to receive either SOC 66 Gy radiotherapy and cisplatin (100 mg/m2 Q3W for three cycles) or nivolumab 240 mg, followed by SOC ...